title: Treatment of relapsing refractory diffuse large cell lymphoma after matched unrelated donor bone marrow transplant with immunosuppression withdrawal and rituximab.
abstract: A 31-year-old man with a diffuse large-cell lymphoma in first refractory relapse received a bone marrow transplant (BMT) from a matched unrelated donor using CAMPATH-1H, carmustine, etoposide, cytarabine and melphalan as conditioning regimen, and methotrexate and tacrolimus for graft-versus-host disease (GVHD) prophylaxis. The transplant was complicated by grade II skin acute GVHD. Lymphoma relapse occurred 4 months post-transplant. Immunosuppression withdrawal plus rituximab induced a complete response. He remains in complete remission (CR) 11 months post-immunosuppression withdrawal and 15 months post-transplant.
authors.affiliation: Department of Blood and Marrow Transplantation, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 423, Houston, TX 77030-4009, USA.
authors.forename: Raymond
authors.initials: R
authors.lastname: Wong
authors.forename: Marcos
authors.initials: M
authors.lastname: de Lima
authors.forename: Daniel
authors.initials: D
authors.lastname: Couriel
authors.forename: Sergio
authors.initials: S
authors.lastname: Giralt
authors.forename: Chitra
authors.initials: C
authors.lastname: Hosing
authors.forename: Munir
authors.initials: M
authors.lastname: Shahjahan
authors.forename: Yee Chung
authors.initials: YC
authors.lastname: Cheng
authors.forename: Jill
authors.initials: J
authors.lastname: Bruton
authors.forename: Richard
authors.initials: R
authors.lastname: Champlin
authors.forename: Issa
authors.initials: I
authors.lastname: Khouri
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000276:immunology*; D018572:Disease-Free Survival; D006801:Humans; D007165:Immunosuppression Therapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy*; D008297:Male; D012008:Recurrence; D000069283:Rituximab; D016879:Salvage Therapy / Q000379:methods*; D019172:Transplantation Conditioning / Q000379:methods
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab